Copyright
©2010 Baishideng Publishing Group Co.
World J Stem Cells. Aug 26, 2010; 2(4): 67-80
Published online Aug 26, 2010. doi: 10.4252/wjsc.v2.i4.67
Published online Aug 26, 2010. doi: 10.4252/wjsc.v2.i4.67
Table 1 Examples of in vivo applications of mesenchymal stem cells
Animal | Disease model | Outcome |
Baboon | Skin graft transplantation | Prolonged skin graft survival[169] |
Mouse | GvHD | Prevention of GvHD[124,170] |
EAE | Prevention of EAE development and improved functional recovery[129,171] | |
CIA | Improved arthritic symptoms[172] | |
NOD | Prevent T-cell mediated beta-cell destruction[173] | |
SLE | Improved symptoms, serological markers and renal function[137] | |
Lung injury | Decreased severity of endotoxin induced lung injury and improved survival[174] | |
Rat | Glomerulonephritis | Accelerate glomerular healing[175] |
Critical size defect | Improved healing and function[176] | |
Experimental colitis | Improved survival and healing[177] | |
Dilated rat cardiomyopathy | Improved cardiac function[178] | |
Heart transplantation | Participate in tissue repair by giving rise to myofibroblasts and cardiomyocytes[179] | |
Myocardial infarction | Improved cardiac function and survival[143] | |
Cerebral ischemia | Reduced gross lesion volume and improved functional recovery[151] |
Table 2 Examples of the therapeutic applications of mesenchymal stem cells in humans
Indications | Source | Rout of administration | Outcome |
Myocardial infarction | Allogenic BM | IV | Increased GSS and EF[148] |
Autologous BM | Intracoronary | Improved LVF[149] | |
Cartilage defect | Autologous BM | Direct site transplantation | Improved clinical symptom and coverage of defect[110] |
Osteogenesis imperfecta | Allogenic BM | IV | Growth acceleration[117] |
Fetal MSC | Intrauterine transplantation | Osteoblastic differentiation and reduced fracture[119] | |
Critical size defect | Autologous BM | Scaffold loaded | Faster full recovery of limb function than bone graft[103] |
MLD and hurler syndrome | Allogenic BM | IV | Improved nerve conduction velocity in MLD patient and increased bone mineral density[167] |
Severe idiopathic aplastic anemia | Allogenic BM | IV | Improved stroma[168] |
Crohn's disease | Adipose derived stem cell | Intralesional | Improved fistula and quality of life[136] |
- Citation: Rastegar F, Shenaq D, Huang J, Zhang W, Zhang BQ, He BC, Chen L, Zuo GW, Luo Q, Shi Q, Wagner ER, Huang E, Gao Y, Gao JL, Kim SH, Zhou JZ, Bi Y, Su Y, Zhu G, Luo J, Luo X, Qin J, Reid RR, Luu HH, Haydon RC, Deng ZL, He TC. Mesenchymal stem cells: Molecular characteristics and clinical applications. World J Stem Cells 2010; 2(4): 67-80
- URL: https://www.wjgnet.com/1948-0210/full/v2/i4/67.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v2.i4.67